Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer

Table 2

Measurement of circulating autoantibodies in the different groups of cancer patients.

	N	OD (Mean ± SD)	𝑃^∗	Number of patients over cut-off limit (%)	𝑃^∗∗
Controls	54	0.5±0.25		1/54 (2)
Cancers	71	0.89±0.44	<0.001	26/71 (37)	<0.001
GI	15	0.97±0.50	0.023	5/15 (33)	0.001
NSCLC	13	1.09±0.65	0.013	6/13 (46)	<0.001
BC	12	0.70±0.45	NS	3/12 (25)	0.017
NET	10	0.92±0.22	<0.001	5/10 (50)	<0.001
UG	10	1.05±0.60	0.001	5/10 (50)	<0.001
M	7	0.54±0.30	NS	1/7 (14)	NS
Others	4	0.69±0.50	NS	1/4 (25)	NS

GI: gastrointestinal cancer; NSCLC: non-small-cell lung cancer; BC: breast cancer; NET: neuroendocrine tumors; UG: urogenital tract cancer; M: melanoma. *Mann-Whitney 𝑈 test; **Fisher's exact test; NS: not significant.